辛伐他汀联合替格瑞洛抗血小板作用的影响被引量：2

下载PDF

导出

摘要目的观察辛伐他汀联合替格瑞洛在治疗冠心病患者中抗血小板的作用。方法将138例冠心病患者随机分成观察组69例(辛伐他汀联合替格瑞洛治疗),对照组69例(辛伐他汀联合氯吡格雷治疗)。分析2组治疗前后血清血小板聚集率、低密度脂蛋白、尿酸、天门冬氨酸转氨酶、肌酸激酶、内皮素-1、6酮-前列腺素F12、血栓素B2的变化,以及治疗后2组不良事件发生率。结果观察组血小板聚集率、低密度脂蛋白、尿酸、天门冬氨酸转氨酶、肌酸激酶、内皮素-1、6酮-前列腺素F12、血栓素B2治疗前后比较差异有统计学意义(P<0.05);对照组除血小板聚集率、天门冬氨酸转氨酶治疗前后比较差异有统计学意义外(P<0.05),其他均无显著差异(P>0.05)。治疗后观察组除尿酸、血栓素B2与对照组比较无显著差异(P>0.05)外,其他均有显著差异(P<0.05)。2组不良反应发生率比较差异有统计学意义(P<0.001)。结论采用替格瑞洛加用辛伐他汀治疗冠心病患者,辛伐他汀能拮抗替格瑞洛的副作用,增强替格瑞洛抗血小板的效果。

作者崔文艳

机构地区丰城市疾病预防控制中心

出处《基层医学论坛》 2016年第26期3645-3647,共3页 The Medical Forum

关键词抗血小板辛伐他汀替格瑞洛氯吡格雷影响

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献14

1HERBERT J M,SAVI P.P2Y12,a new platelet ADP receptor target ofclopidogrel [J].Semin Vase ; ( Med),2003,3(2): 113-122.
2WALLENT L,BL CKL,R RC,et al.Ticagrelor versus clopidogrel inpatients with acute coronary synromes [J].N Engl J Med,2009,361(11):1045-1057.
3LI H,BUTLER K,YANG L,et al. Pharmacokinetics and tolerability ofsingle and multiple doses of ticagrelor in healthy Chinese subjects : anopen-label,sequential, two-cohort, single-sentre study [Jj.Clin DrugInvestig ,2012,32(2): 87-97.
4HIASA Y,TENG R,EMANUELSSON H.Pharmacokinetics and safetyof ticagrelor in Asian patients with stable coronary artery disease [J].Cardiovasc lrrterv Ther, 2014,29(4) :324-333.
5朱建兵,张俊峰.冠心病抗栓药物新进展[J].国际心血管病杂志,2014,41(3):163-166. 被引量：11
6徐亚伟,李宪凯.不断更新的抗栓治疗——2012年ACCF/AHA不稳定性心绞痛和非ST段抬高性心肌梗死指南解读[J].中国循环杂志,2012,27(S01):12-15. 被引量：16
7HLTUN W W.SteinhubI SR Ticagrelor: :the first novel reversible P2Y(12)inhibitor[J],Expert Opin Pharmacother,2013,14(2):237-245.
8龚世菊,张志刚,谭文明.辛伐他汀与替格瑞洛联用后对相互临床疗效的影响[J].中国医院用药评价与分析,2015,15(6):737-739. 被引量：3
9马文韬,颜红兵.新型的口服抗血小板药物替格瑞洛[J].中华老年心脑血管病杂志,2012,14(11):1217-1218. 被引量：50
10CATTANEO M, F'AIONI L M.Why does ticagrelor induce dyspnea[J].Thromb Haemost,2012,108(6) : 1031-1036.

二级参考文献40

1徐亚伟,李宪凯.不断更新的抗栓治疗——2012年ACCF/AHA不稳定性心绞痛和非ST段抬高性心肌梗死指南解读[J].中国循环杂志,2012,27(S01):12-15. 被引量：16
2Huber K, Hamad B,Kirkparick P. Fresh from the pipeline ti- cagrelor. Nat Rev Drug Discov, 2011,10:255-256.
3Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopi dogrel in patients with acute coronary syndromes. N Engl J Med,2009,361,1045-1057.
4Cannon CP, Harrington RA, James S, et al. Comparison of ti- cagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO) :a randomised double-blind study. Lancet, 2010,375 : 283-293.
5James SK,Roe MT, Cannon GP, et al. Ticagrelor versus clopi dogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective random ized PLATelet inhibition and patient outcomes(PLATO) Tri- al. BMJ ,2011,342 :d3527.
6Held C, ]ksenblad N, Bassand JP, et al. Ticagrelor versus clopi dogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery-results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coil Car- diol, 2011,57 : 672-684.
7Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias andelinical bradyarrhythmicevents in pa tients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO(platelet inhibition and patient out- comes)trial. J Am Coil Cardiol,2011,57: 1908-1916.
8Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction ( TRITON-T1MI 38) : double blind, randomised controlled trial [J]. Lancet, 2009, 373(96653: 723-731.
9Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes [J]. N Engl J Med, 2009, 361(11): 1045- 1057.
10Bhatt DL, Stone GW, Mahaffey KW,et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events [J]. N Engl J Med, 2013, 368(14) : 1303 -1313.